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The GeneXpert MTB/RIF assay (Xpert) is a novel automated diagnostic tool for tuberculosis but its optimal placement in the
healthcare system has not been determined.The objective of this study was to determine the possibility of additional case detection
for pulmonary tuberculosis (PTB) by offering Xpert to smear-negative patients in a low-HIV burden setting with noMycobacterium
tuberculosis (M.tb.) culture facilities. Patients routinely presenting with symptoms suggestive of PTB with negative smears were
offered single Xpert test on a fee-paying basis. Data were retrospectively reviewed to determine case detection in patients tested
from February to December 2013. Symptoms associated with a positive test were analysed to determine if refinement of clinical
criteria would reduce unnecessary testing. 258 smear-negative patients were included and M.tb. was detected in 55 (21.32%,
𝑛 = 55/258). Using standard clinical assessment for selection, testing 5 patients detected one case of smear-negative PTB. These
results demonstrate that fee-paying Xpert service in low-income setting can increase TB case confirmation substantially and further
systematic studies of health economic implications should be conducted to determine optimal implementation models to increase
access to Xpert in low- and middle-income countries.
1. Introduction
Tuberculosis (TB) continues to be a major public health
problem, with 8million cases and 1.3million deaths each year
[1]. One of the key challenges for TB control is to increase
case detection and early treatment, thereby interrupting
transmission chains and reducing individual morbidity. The
most widely used test for TB, sputum smear microscopy, has
a sensitivity of only 50% of active cases which contributes
to delayed diagnosis resulting in continued transmission
[2, 3]. In an advanced diagnostic setting, facilities such as
culture, drug susceptibility testing (DST), and commercial
molecular diagnosticsmay be available, but these facilities are
lacking in most hospitals in high burden countries. Sputum
smears with chest X-ray (CXR), where available, are the tests
routinely applied for TB diagnosis. It is crucial to implement
improved diagnostics in these endemic settings if we are to
reach the targets of case detection, reduction inmortality, and
prevalence of the disease [4, 5].
Derivations from case burden estimates suggest that
only around 70% of active TB cases are diagnosed using
current strategies [1]. The development and implementation
of the Xpert assay (Cepheid, Sunnyvale, CA, USA), which
has high sensitivity in detection of smear-negative TB, has
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raised hopes of increased case detection in low- and middle-
income countries (LMICs). Xpert is the only fully automated
real-time DNA-based test which can detect both TB and
rifampicin resistance (RR) [6, 7]. The test is based on a
heminested PCR test which detects the presence ofMycobac-
terium tuberculosis complex bacilli [8].The PCR target, an 81-
base-pair region of the rpoB gene, is the rifampicin resistance
determining region (RRDR) [6, 9].The reactions take place in
a single-use cartridgemaking it easy to operate, without cross
contamination, and giving a result in as little as 2 hours and
thus potentially decreasing default due to delayed diagnosis
[7, 10].
In the most recent meta-analysis, Xpert as an initial
replacement for smear microscopy showed a pooled sensi-
tivity of 89% (95% credible interval CrI 85% to 92%) and
pooled specificity of 99% (95% CrI 98% to 99%), and as an
add-on test following a negative smear microscopy, pooled
sensitivity and specificity were 67% (95% CrI 60% to 74%)
and 99% (95% CrI 98% to 99%), respectively [11]. For RR
detection, it achieved a pooled sensitivity of 95% (95% CrI
90% to 97%) and a pooled specificity of 98% (95% CrI 97%
to 99%) [11]. The test was first endorsed by WHO in 2010
[11, 12] and revised recommendations in 2013 included a
recommendation that Xpert be used in all suspectedTB cases,
with the acknowledgement that this has substantial resource
limitations [13].
However, despite a substantial negotiated price reduction
on the test for LMICs, the 10USD per cartridge remains
expensive for low-income countries which often have per
capita healthcare expenditure of <30USD [14]. There have
been limited reports of Xpert implementation on a fee-
paying basis in such settings, with the majority of projects
implementing free at point of care, a model which is depen-
dent on sustained aid funding. Although the test cost is
high to the patient, a confirmed diagnosis can avert often
lengthy differential investigations and exploratory treatment
which may cost substantially more. We therefore examined
the impact on case detection of implementing Xpert as an
optional fee-paying service to patients with suspected smear-
negative TB.
In Nepal, the estimated incidence of TB is 163 per 100,000
with a prevalence rate of 241 per 100,000 population. In
2012-13, theNepal Tuberculosis Programme (NTP) registered
17,788 sputum smear-positive cases and 8,367 sputum smear-
negative cases [15]. In commonwithmany LMICs, many pul-
monary TB cases treated in the private sector go unreported
and therefore there is likely to be discrepancy between official
figures and the true numbers being diagnosed and treated.
Although multidrug resistant tuberculosis (MDR TB) rates
remain relatively low, at 2.2% in new and 17.2% among
retreatment cases, only 262, one-quarter of the estimated
MDR cases, were treated via the national programme in 2012-
13 [15]. The positive predictive value of rifampicin resistance
detection usingXpert in an unselected patient populationwill
be low and confirmation of MDR is necessary before MDR
treatment is initiated.
A recent Cochrane study concluded that more research
would be helpful in evaluating the use of Xpert in TB
programmes in high TB burden settings [11].
We report here the experience of implementing Xpert at
a general hospital in Kathmandu, Nepal, and determine the
number needed to test in order to detect one active case of
smear-negative TB.
2. Materials and Methods
Patan Hospital is a 450-bed government general hospital
providing emergency and elective outpatient and inpatient
services, located in the Lalitpur area of the Kathmandu valley.
The laboratory services are limited with acid-fast bacilli
smear available but no provision forM.tb. culture.
From February 18, 2013, an Xpert machine was made
available for testing. Clinical practitioners both from within
and outside the hospital were invited to refer patients with
symptoms consistent with TB and three negative sputum
smears to testing by Xpert. Patients offered the test were
informed about the test evaluation and asked for consent
to collect baseline data on demographics and symptoms at
presentation. This study was approved by the Institutional
Review Board of Patan Hospital.
Patients with 3 negative Ziehl-Neelsen (ZN) sputum
smears were referred for Xpert testing at the treating clin-
ician’s discretion. A new sputum sample was collected for
Xpert testing. Data was collected on history of persistent
cough (≥2 weeks), fever, drenching night sweats, weight loss
(>1.5 kg in a month), loss of appetite, malaise, and shortness
of breath or chest pain.
CXR reports were collected where available. For further
analysis, CXR features were classified by the study investiga-
tors according to radiologist’s report as upper lobe infiltrates,
pleural effusion, diffuse infiltrates, cavitary lesions, other
infiltrates, consolidation, other abnormalities, and normal.
CXR reported as patchy infiltrates, bilateral infiltrates, and
infiltrates without a specified location was classified as “other
infiltrates.” “Other abnormalities” comprised of pneumotho-
rax, hyperinflation, lung abscess, mediastinal opacity, nodu-
lar opacity, mass lesion, and pleural thickening.
At Patan Hospital, the acid-fast bacilli microscopy is
performed by experienced laboratory personnel following
the guidelines set by the NTP and is monitored by the NTP
external quality assessment (EQA) scheme.The sputum sam-
ple for the Xpert was processed according to manufacturer’s
guidelines. The patients were charged NPR 2000 (∼20USD)
per test. This cost included freight charges (∼$3 per car-
tridge), staffing, annual machine calibration ($450 per year),
and annual maintenance charge (∼$2,700 per year). The HIV
status was reported by the patient but no confirmatory HIV
testing was performed. Data on the treatment outcome was
not collected.
We further examinedwhether restricting the tested popu-
lation would miss cases of TB or improve efficiency of testing
and reduce unnecessary patient charges. We determined the
number needed to test if the tested population was restricted
to (1) those with 2 or more symptoms consistent with TB
(fever, night sweats, persistent cough (≥2 weeks), weight loss
(≥1.5 kg in a month), malaise, shortness of breath, or chest
pain) or (2) those with CXR abnormalities and 2 or more
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symptoms or (3) those with only the CXR abnormalities
found in the Xpert positive group.
Categorical variables were compared between patient
groups testing positive and negative by Xpert using Fisher’s
exact test with a 𝑃 value of ≤0.05 considered as significant.
3. Results
Between February 18, 2013, and December 30, 2013, 258
smear-negative patients were tested by Xpert on sputum.
Eighty-nine patients were referred from other hospitals
throughout the Kathmandu valley, while 169 were from Patan
Hospital clinics. Data were not systematically collected on
patients who were smear-negative but not offered the test
during the study period but no patients declined the test when
offered at PatanHospital.Nopatient declined consent for data
collection and we therefore included all Xpert tested patients
in the analysis.
During the study period, there were 2,222 new patients
tested by smear microscopy at Patan Hospital. Of these,
1,070 had 3 negative sputum smears and 196 had at least
one positive sputum smear. The remaining 956 patients did
not complete 3 sputum smears. Therefore, 169/1070 (15.8%)
of diagnostic subjects were offered an Xpert test. In the
majority of cases, this was due to an alternative diagnosis
being reached or symptom resolution/improvement during
the smear and CXR diagnostic process, but this was not
systematically evaluated.
Xpert was positive for M.tb. in 55 (𝑛 = 55/258, 21.3%)
patients. Therefore, 4.7 patients needed to be tested to detect
one active TB case. All patients with a positive Xpert test were
referred for free treatment in the appropriate NTP DOTS
facility.
A third of patients (𝑛 = 93/258, 37.98%) was female and
the median age was 52 (interquartile range IQR 33–68). Four
children were included (13, 15, and two 17 years of age).
There were 2 patients (𝑛 = 2/258, 0.8%) with a positive
result for rifampicin resistant TB by the Xpert test. The first
patient was referred for sputum culture and phenotypic drug
susceptibility testing at a tertiary centre (GENETUP, Nepal).
The second rifampicin resistant patient was untraceable
for follow-up by the phone number provided. No patient
reported known HIV infection.
Table 1 shows the clinical features of the patients.The only
clinical feature to show a statistically significant difference
between the groups was shortness of breath, which was more
common among Xpert negative patients (56.6 versus 72.2%,
𝑃 = 0.04). As this finding nevertheless occurred in half of
Xpert positive patients, it was not appropriate for refining the
group of patients tested.
CXR was available for 187 patients (Table 2). Thirteen
patients (𝑛 = 13/187, 6.9%) had no abnormality detected on
CXR. Upper lobe infiltrates (𝑃 = 0.03) and cavitary lesions
(𝑃 = 0.03) were more common among the Xpert positive
group. Consolidation (𝑃 = 0.04) was not evident among the
Xpert positive group while it was reported in 9.4% of Xpert
negative patients.
Table 1: Comparison of clinical features of 251 patients with
suspected smear negative TB testing positive and negative by Xpert.
Clinical features Xpert positive Xpert negative 𝑃 value
Cough 38 (71.7) 143 (72.2) 1
Fever 28 (52.8) 90 (45.5) 0.36
Night sweats 23 (43.4) 61 (30.8) 0.10
Loss of appetite 39 (73.6) 140 (70.7) 0.74
Weight loss 31 (58.5) 106 (53.5) 0.54
Malaise 42 (79.3) 164 (82.8) 0.55
Shortness of
breath/chest pain 30 (56.6) 143 (72.2) 0.04
Total 53 (100) 198 (100)
∗Clinical questionnaire was not available for 7 patients.
kg = kilogram.
Table 2: Comparison of chest X-ray features of 187 patients testing
positive or negative by Xpert.
Chest X-ray findings Xpert positive Xpert negative 𝑃 value
Upper lobe infiltrates 12 (31.57) 22 (14.86) 0.03
Cavitary lesions 5 (10.52) 5 (4.05) 0.03
Pleural effusion 9 (29.68) 27 (18.24) 0.49
Diffuse infiltration 7 (18.42) 26 (17.56) 1
Consolidation 0 14 (9.45) 0.04
Others 0 11 (6.75) 0.12
Normal 1 (2.6) 12 (8.10) 0.30
Other infiltrates 6 (13.15) 24 (16.89) 1
Infiltrates not in
upper lobes 5 (13.15) 21 (14.18) 1
Total 39 (100) 148 (100)
∗Sum of the categories is greater than the total number of patients as one
patient may be in more than one category.
No clinical questionnaire was available for 7 patients,
leaving 251 patients in the symptom analysis (Table 3). If
the Xpert testing was restricted to patients with 2 or more
symptoms, the number needed to test was not altered and
remained at 4.6 (𝑛 = 50/232, 21.6% positive). Three cases of
TB would have been missed.
187 patients had an available questionnaire and CXR
report. If CXR abnormalities and 2 clinical symptoms were
required for Xpert testing, the number needed to test was
4.5 (𝑛 = 36/163, 22.1%). Three cases of TB would have been
missed.
187 patients had CXR available. If testing were restricted
to only those with an abnormal CXR showing at least one
of the four characteristics, upper lobe infiltrates, cavitary
lesions, pleural effusion, or infiltrates, then the number
needed to test was 4 (𝑛 = 38/152 = 25%). 1 case would have
been missed.
4. Discussion
This report demonstrates that application of Xpert testing as
a fee-paying service in a general hospital can substantially
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Table 3: Number of patients detected as positive by GeneXpert using different inclusion criteria for testing.
Patients
Number of
patients with
information
𝑛 (%)
Number of
patients
tested
Numbers of
Xpert positive
𝑛 (%)
Number
needed to test
Numbers of
patients not
meeting the
criteria
Xpert positive in
group not meeting
criteria
𝑛 (%)
At least 2
symptoms∗ 251 (93.7) 232 50 (21.6) 4.6 19 3 (15.8)
At least 2
symptoms +
CXR∗∗
187 (72.5) 163 36 (22.1) 4.5 24 3 (12.5)
At least the 4
listed CXR
abnormalities
187 (72.5) 152 38 (25.0) 4.0 35 1 (2.9)
∗7 patients had no available information of symptoms and were therefore excluded.
∗∗71 patients did not have information of CXR report and were therefore excluded.
increase the yield of confirmed TB cases. Five patients need
to be tested to detect one TB case by applying simple routine
criteria to select smear-negative TB suspects. During the
same time period, there were 196 smear-positive TB cases
at Patan Hospital and the implementation of Xpert therefore
resulted in a 28.1% (𝑛 = 55/196) increase in confirmed TB
cases.
We assumed that the specificity of Xpert is high, as every
study performed to date and meta-analysis has indicated
consistently high specificity of 99% [10, 11, 16]. Therefore,
although there is no culture confirmation for comparison,
this was not an evaluation of diagnostic accuracy, which
has been comprehensively reported elsewhere and it can be
reasonably assumed that these cases are genuine, and the rate
of false positive diagnosis is unlikely to exceed that of culture.
In areas of high TB prevalence such as Nepal, the
majority of suspected TB cases are assessed by sputum smear
microscopy and, where available, by CXR. Patients are often
placed onto TB treatment on the basis of persistent cough
or abnormal CXR alone. Modelling studies have indicated
that Xpert scale-up may not increase the overall number of
cases initiated on treatment due to these pragmatic empirical
treatment practices. Instead, Xpert will divert treatment away
from “false cases” to “true” smear-negative TB cases, thereby
increasing the accuracy of treatment and cost-effectiveness,
while reducing the burdens of toxicity and opportunity cost of
treatment in patients who do not in fact have TB [17, 18]. The
ability of Xpert to rapidly confirmTB in smear-negative cases
offers the possibility of improving early TB case detection,
but due to costs, recommendations for high burden, low-
resource settings have so far focused on applying Xpert to
HIV-infected individuals (where the sensitivity of smear is
especially low and the complications of missed diagnosis
are more severe) and patients with risk factors for MDR
TB. Although WHO recommends applying the test to all
smear-negative cases, the recommendation comes with the
caveat that this is not financially feasible in most settings
[13]. The low positive predictive value of Xpert for rifampicin
resistance in a lowMDR prevalence test populationmust also
be considered. There has been considerable debate around
the possibility of providing Xpert on a fee-paying basis to
patients in low-income, high burden settings [19]. This study
demonstrates that both uptake and case detection can be
high in a targeted approach but further studies should be
performed to determine the health economic impacts of such
application, both on the individual patients including the
opportunity costs of alternative health investigations and on
household finances of testing costs and on hospital resource
allocation.
The impact of delayed TB detection is threefold: firstly,
morbidity to the individual is increased and in many cases
will persist beyond the disease episode in severe permanent
lung damage; secondly, undetected smear-negative TB will
become progressively more infectious and transmit within
the community; and finally the economic impact on the
household is magnified by repeated visits to healthcare
facilities, differential diagnostic testing and treatments, and
loss of earnings due to healthcare seeking and morbidity.
The Xpert assay has also increased early detection of
MDR-TB, particularly when applied to high-risk groups in
accordance with WHO recommendations. Prior to applica-
tion of this assay, patients at high risk for MDR TB would
have to be referred to a tertiary setting and wait 6 to 8
weeks for results of phenotypic drug susceptibility testing
resulting in high loss to follow-up and delays in treatment
initiation. The line probe assays for MDR diagnosis have
also largely been limited to tertiary centres in LMICs. In
an unselected patient group without MDR risk factors and
a low background prevalence of MDR TB, the positive
predictive value of Xpert for rifampicin resistance is low and
the result should be confirmed by a second test. However,
early identification of possible MDR cases is key to reducing
community transmission and reducing the incidence ofMDR
TB. The first patient positive for rifampicin resistant TB
by Xpert in this study was referred to a tertiary centre for
confirmatory testing by phenotypic DST according to the
national guidelines. The phenotypic DST showed the patient
was infected with TB resistant to isoniazid, rifampicin,
streptomycin, and ethambutol. Without Xpert testing, this
patient would have received a first line treatment regimen for
a minimum of 5 months before being tested by phenotypic
DST. The loss to follow-up of the second case despite the use
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of a rapid test demonstrates the problems associated with TB
control beyond the need for accurate tests.This case could not
be confirmed as a true positive for MDR and may not have
received any TB treatment.
It is not clear how many of the patients testing positive
for M.tb. by Xpert in this study would have been started
on TB treatment based on the judgement of the treating
clinician if Xpert testing was not available [20]. In the
previous year (2011-2012) at Patan Hospital, 21 patients were
empirically treated for TB, approximately one-third of those
detected by Xpert during the study period (1.75/months
versus 5.65/months, resp.). It is possible that the availability
of Xpert increased the recognition of TB symptoms, although
we can claim that in this endemic setting TB awareness is con-
sistently high among clinicians. Conversely, it is possible that
a negative Xpert testmay have discouraged treatment in some
cases which would otherwise have been treated, although
clinicians were informed that a negative Xpert test does not
exclude a TB diagnosis. Patients with a strong possibility of
pulmonary TB despite a negative Xpert test were referred for
further investigations including culture at a tertiary centre.
The rate of smear positivity at Patan is 9.28% which is consis-
tent with the results in other areas of similar endemicity; it is
therefore unlikely that the Xpert diagnosis was inflated due to
low smear microscopy confirmation [21–23].
The cost to the patients of the assay was 20USD (which is
equivalent to the price of eight CXRs in our hospital), includ-
ing the full cost to the hospital of performing the assay and
maintaining the service. Despite this, no clinician reported
patients refusing the test for financial reasons, although
this was not systematically evaluated. Studies of the patient
acceptability of testing should be performed to determine the
relative cost benefits for the patients of receiving a fee-paying
Xpert test versus the traditional diagnostic route.
Scale-up of Xpert testing is underway in Nepal but
funding is not available to provide Xpert testing free to all
patients with suspected smear-negative TB and is unlikely
to be so in the near to medium term. This is also true in
other LMICs. In India, it was calculated that providing Xpert
to all smear-negative TB suspects would consume the entire
national healthcare budget [17].
Our study is consistent with other studies which have
suggested the benefit of Xpert in smear-negative patients in
developing countries [11, 24, 25].Themajority of these studies
have been carried out in Africa where there is a substantially
higher HIV burden than in South Asia. Three studies have
been reported from low-HIV prevalence regions, including
Peru and two hospitals (Hinduja Hospital and Christian
Medical College Hospital) in India [8, 18, 25].
We examined the clinical features of groups testing posi-
tive and negative by Xpert to determine if further refinement
of eligibility for testing criteria could guide the application
of Xpert and reduce unnecessary testing and thereby costs
to the patient. The number needed to test was reduced to
4 by restricting patients tested to only those with specific
CXR criteria consistent with TB, while only a single case
was missed. This strategy should be evaluated in a larger
multicentre study to determine the optimal referral algorithm
for Xpert testing in the general hospital setting.
By using only the classical broad definition of TB symp-
toms and CXR interpretation, the number needed to test
for a single confirmed case of active TB is as low as five in
this general hospital. Although smear microscopy, due to its
simplicity, speed, and low cost, is used widely in low-resource
settings, the low sensitivity precludes it from being an ideal
test. The requirement for a rapid, simple TB diagnostic
is evidenced by the widespread application of commercial
serological tests which are inaccurate. These tests are widely
provided at a cost to the patient and used to determine
medical treatment. The government of India has recently
banned the use of these tests following systematic evaluation
by WHO [26]. Although the Xpert has several limitations,
including requirement for stable electricity supply, limited
temperature range, availability of maintenance, and bulky
consumables, wider availability of the accurate Xpert assay
may counter the use of these serological tests by providing
a viable alternative to the patient and healthcare provider.
It is highly probable that a small number of cases of TB
were missed in this study as Xpert does not have as high
sensitivity as culture. There is a danger that clinicians will
“exclude” a TB diagnosis on the basis of a negative Xpert
test and it is important that education is carried out to
ensure clinicians are aware of the test limitations prior to
the test being implemented. However, it is not sustainable to
implement TB culture facilities at general hospitals in South
Asia and the long turnaround of results means loss to follow-
up in the diagnostic pathway is high. This study was not
an assessment of Xpert sensitivity and specificity, as this has
been comprehensively evaluated in comparison with culture
by others.
5. Conclusion
Our study has shown that by applying Xpert to test for smear-
negative TB on a fee-paying basis in a general hospital in
Nepal, five patients need to be tested to detect one case
of active TB. Restriction of criteria for testing using CXR
features can reduce the number needed to 4. Further research
is needed evaluating the cost effectiveness, patient accept-
ability and impact on overall out-of-pocket expenditure of
Xpert testing provided at a direct cost to the patient, to
determine the optimal sustainable use of this technology
while maximizing equality of access.
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